Forigerimod acetate is under clinical development by Immupharma and currently in Phase II for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase II drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Forigerimod acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Forigerimod acetate overview

Forigerimod (lupuzor, IPP-201101, rider mod or P140) is under development for the treatment of systemic lupus erythematosus (SLE), asthma, Crohn''s Disease, rheumatoid arthritis, periodontitis and chronic inflammatory demyelinating polyneuropathy. The drug candidate is administered through the subcutaneous route. The drug candidate acts by modulating CD4 T cell.

Immupharma overview

Immupharma (Immupharma) is a biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. Immupharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; BioCIN, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and P140, a drug developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. It has operations in France and Switzerland. Immupharma is headquartered in London, Greater London, the UK.

For a complete picture of Forigerimod acetate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.